EcoDrugPlus

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSAMXG00000016128
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSAMXG00000034250
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSAMXG00000040472
Gene Symbol: GBA1
3 Cross references
255 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSAMXG00000042385
Gene Symbol: GRIA2
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSAMXG00000042054
Gene Symbol: GRIN2A
1 Cross references
225 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSAMXG00000002516
Gene Symbol: GRIN2A
1 Cross references
223 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSAMXG00000040741
Gene Symbol: GRIN2B
1 Cross references
261 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSAMXG00000017477
Gene Symbol: GRIN2C
3 Cross references
247 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSAMXG00000039510
Gene Symbol: GRIN2C
3 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSAMXG00000021254
Gene Symbol: GRIN3A
4 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSAMXG00000018792
Gene Symbol: GRIN3B
1 Cross references
224 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3b

Ensembl ID : ENSAMXG00000006305
Gene Symbol: GRIN3B
1 Cross references
227 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).